Payment overview · 2025
General Payments
$1,284.60
68 reported records · 17 companies
Healthcare provider profile · identity verified
Todd David Pascarelli, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROCHELLE PARK, NJ · NPI 1316026255
Verified facts
What the public records show
CMS Open Payments records show Todd David Pascarelli, MD received $1,284.60 in general payments during 2025 across 68 reported records.
PFIZER INC. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rexulti.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $221.32 | 17.2% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $161.53 | 12.6% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $148.63 | 11.6% | 10 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $122.43 | 9.5% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $113.80 | 8.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.80 | 8.8% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $76.84 | 6.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.02 | 4.3% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $48.95 | 3.8% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $41.62 | 3.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $36.19 | 2.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.87 | 2.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.63 | 2.6% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.87 | 1.9% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $17.78 | 1.4% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $16.67 | 1.3% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $16.65 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,284.60 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $221.32 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $161.53 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $161.53 | 10 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $122.43 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $113.80 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $90.89 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $79.63 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $76.84 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $69.00 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.64 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $48.95 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.63 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $24.87 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.93 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 91 |
| Losartan Potassium | Losartan Potassium | 247 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 57 |
| Ezetimibe | Ezetimibe | 165 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 42 |
| Alprazolam | Alprazolam | 144 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 35 |
| Metformin Hcl | Metformin Hcl | 129 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 36 |
| Simvastatin | Simvastatin | 108 | 28 |
| Potassium Chloride | Potassium Chloride | 92 | 28 |
| Gabapentin | Gabapentin | 87 | 26 |
| Furosemide | Furosemide | 85 | 21 |
| Jardiance | Empagliflozin | 80 | 19 |
| Metformin Hcl Er | Metformin Hcl | 80 | 24 |
| Ozempic | Semaglutide | 77 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 21 |
| Allopurinol | Allopurinol | 72 | 14 |
| Famotidine | Famotidine | 71 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 13 |
| Lisinopril | Lisinopril | 62 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 17 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Eliquis | Apixaban | 57 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 14 |
| Omeprazole | Omeprazole | 49 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Tramadol Hcl | Tramadol Hcl | 35 | 12 |
| Lorazepam | Lorazepam | 34 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 13 |
| Azithromycin | Azithromycin | 17 | 16 |
| Diazepam | Diazepam | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Baclofen | Baclofen | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Tadalafil | Tadalafil | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,284.60 · 68 records | PFIZER INC. | AREXVY, Arikayce, Bimzelx, CAPVAXIVE, Cologuard Collection Kit, DUPIXENT, GARDASIL 9, JARDIANCE, OCTAGAM IMMUNE GLOBULIN (HUMAN), OPSUMIT, OTEZLA, Ozempic, PREVNAR 20, Prolastin-C Liquid, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TREMFYA, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error